Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that occurs in two clinically indistinguishable forms: sporadic (SALS) and familial (FALS), the latter linked to several gene mutations, mostly inheritable in a dominant manner. Nearly 20% of FALS forms are linked to mutations in the Cu/Zn superoxide dismutase (SOD1) gene. Research on ALS relies on transgenic models and particularly on mice carrying a glycine-to-alanine conversion at the 93rd codon (G93A) of the hSOD1 gene. Although G93A transgenic mice have been widely employed in clinical trials and basic research, doubts have been recently raised from numerous reliable sources about their suitability to faithfully reproduce human disease. Besides, the scientific community has already foreseen swine as an attractive and alternative model to nonhuman primates for modeling human diseases due to closer anatomical, physiological and biochemical features of swine rather than rodents to humans. On this basis, we have produced the first swine ALS model by in vitro transfection of cultured somatic cells combined with somatic cell nuclear transfer (SCNT). To achieve this goal we developed a SOD1G93A (superoxide dismutase 1 mutated in Gly93-Ala) vector, capable of promoting a high and stable transgene expression in primary porcine adult male fibroblasts (PAF). After transfection, clonal selection and transgene expression level assessment, selected SOD1G93A PAF colonies were used as nuclei donors in SCNT procedures. SOD1G93A embryos were transferred in recipient sows, and pregnancies developed to term. A total of 5 piglets survived artificial hand raising and weaning and developed normally, reaching adulthood. Preliminary analysis revealed transgene integration and hSOD1G93A expression in swine tissues and 360° phenotypical characterization is ongoing. We believe that our SOD1G93A swine would provide an essential bridge between the fundamental work done in rodent models and the reality of treating ALS.

Keywords:
Animal model, Swine, Amyotrophic lateral sclerosis, Somatic cell nuclear transfer, Cu/Zn superoxide dismutase 1, SOD1G93A, Pig
1.
Kuncl RW, Crawford TO, Rothstein JD, Drachman DB: Motor neuron diseases; in Asbury AK, McKhann GM, McDonald WI (eds): Diseases of the Nervous System. Philadelphia, Saunders, 1992, pp 1179-1208.
2.
Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng H-X, Rahmani Z, Krizus A, McKenna-Yasek D, Cayabyab A, Gaston SM, Berger R, Tanzi RE, Halperin JJ, Herzfeldt B, Van den Bergh R, Hung W-Y, Bird T, Deng G, Mulder DW, Smyth C, Laing NG, Soriano E, Pericak-Vance MA, Haines J, Rouleau GA, Gusella JS, Horvitz HR, Brown RH Jr: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
3.
Liscic RM, Breljak D: Molecular basis of amyotrophic lateral sclerosis. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:370-372.
4.
Lemmens R, Van Hoecke A, Hersmus N, Geelen V, D'Hollander I, Thijs V, Van Den Bosch L, Carmeliet P, Robberecht W: Overexpression of mutant superoxide dismutase 1 causes a motor axonopathy in the zebrafish. Hum Mol Genet 2007;16:2359-2365.
5.
Wang J, Farr GW, Hall DH, Li F, Furtak K, Dreier L, Horwich AL: An ALS-linked mutant SOD1 produced a locomotor defect associated with aggregation and synaptic dysfunction in neurons of Caenorhabditis elegans. PLoS Genet 2009;5:e1000350.
6.
Mockett RJ, Radyuk SN, Benes JJ, Orr WC, Sohal RS: Phenotypic effects of familial amyotrophic lateral sclerosis mutant Sod alleles in transgenic Drosophila. Proc Natl Acad Sci USA 2003;100:301-306.
7.
Turner BJ, Talbot K: Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 2008;85:94-134.
8.
Schnabel J: Neuroscience: standard models. Nature 2008;454:682-685.
9.
Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, Bostrom A, Theodoss J, Al-Nakhala BM, Vieira FG, Ramasubbu J, Heywood JA: Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 2008;9:4-15.
10.
Benatar M: Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 2007;26:1-13.
11.
Van Den Bosch L: Genetic rodent models of amyotrophic lateral sclerosis. J Biomed Biotechnol 2011;2011:348765.
12.
Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny GM, Mac Arthur RB, Mitsumoto H, Neville HE, Boylan K, Mozaffar T, Belsh JM, Ravits J, Bedlack RS, Graves MC, Mc Cluskey LF, Barohn RJ, Tandan R: Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007;6:1045-1053.
13.
Lunney JK: Advances in swine biomedical model genomics. Int J Biol Sci 2007;3:179-184.
14.
Whyte JJ, Prather RS: Genetic modifications of pigs for medicine and agriculture. Molecular reproduction and development. Mol Reprod Dev 2011;78:879-891.
15.
Bendixen E, Danielsen M, Larsen K, Bendixen C: Advances in porcine genomics and proteomics - a toolbox for developing the pig as a model organism for molecular biomedical research. Brief Funct Genomics 2010;9:208-219.
16.
Bugos O, Bhide M, Zilka N: Beyond the rat models of human neurodegenerative disorders. Cell Mol Neurobiol 2009;29:859-869.
17.
Lind NM, Moustgaard A, Jelsing J, Vajta G, Cumming P, Hansen AK: The use of pigs in neuroscience: modelling brain disorders. Neurosci Biobehav Rev 2007;31:728-751.
18.
Bjarkam CR, Nielsen MS, Glud AN, Rosendal F, Mogensen P, Bender D, Doudet D, Møller A, Sørensen JC: Neuromodulation in a minipig MPTP model of Parkinson disease. Br J Neurosurg 2008;22(suppl 1):S9-S12.
19.
Kragh PM, Nielsen AL, Li J, Du Y, Lin L, Schmidt M, Bøgh IB, Holm IE, Jakobsen JE, Johansen MG, Purup S, Bolund L, Vajta G, Jørgensen AL: Hemizygous minipigs produced by random gene insertion and handmade cloning express the Alzheimer's disease-causing dominant mutation APPsw. Transgenic Res 2009;18:545-558.
20.
Lorson MA, Spate LD, Samuel MS, Murphy CN, Lorson CL, Prather RS, Wells KD: Disruption of the survival motor neuron (SMN) gene in pigs using ssDNA. Transgenic Res 2011;20:1293-1304.
21.
Uchida M, Shimatsu Y, Onoe K, Matsuyama N, Niki R, Ikeda JE, Imai H: Production of transgenic miniature pigs by pronuclear microinjection. Transgenic Res 2001;10:577-582.
22.
Niwa H, Yamamura K, Miyazaki J: Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991;108:193-199.
23.
Brunetti D, Perota A, Lagutina I, Colleoni S, Duchi R, Calabrese F, Seveso M, Cozzi E, Lazzari G, Lucchini F, Galli C: Transgene expression of green fluorescent protein and germ line transmission in cloned pigs derived from in vitro transfected adult fibroblasts. Cloning Stem Cells 2008;10:409-419.
24.
McKnight RA, Shamay A, Sankaran L, Wall RJ, Henninghausen L: Matrix-attachment regions can impart position-independent regulation of a tissue-specific gene in transgenic mice. Proc Natl Acad Sci USA 1992;89:6943-6947.
25.
Lagutina I, Lazzari G, Galli C: Birth of cloned pigs from zona-free nuclear transfer blastocysts developed in vitro before transfer. Cloning Stem Cells 2006;8:283-293.
26.
Niemann H, Rath D, Wrenzycki C: Advances in biotechnology: new tools in future pig production for agriculture and biomedicine. Reprod Domest Anim 2003;38:82-89.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.